NASDAQ: SNTI - Senti Biosciences, Inc.

Yield per half year: +14.45%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Senti Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

more details
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2022-06-09
ISIN US81726A1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sentibio.com
Цена ао 3.84
Change price per day: -17.76% (3.66)
Change price per week: -23.99% (3.96)
Change price per month: -29.34% (4.26)
Change price per 3 month: +39.35% (2.16)
Change price per half year: +14.45% (2.63)
Change price per year: +598.38% (0.431)
Change price per 3 year: -69.55% (9.885)
Change price per 5 year: 0% (3.01)
Change price per 10 year: 0% (3.01)
Change price per year to date: -24.75% (4)
All parameters

Underestimation

Title Value Grade
P/S 9.51 1
P/BV 0.3641 10
P/E 0 0
EV/EBITDA -0.4243 0
Total: 5

Efficiency

Title Value Grade
ROA, % -59.47 0
ROE, % -106.19 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.6122 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 2912.94 10
Yield Ebitda, % 186.62 10
Yield EPS, % 1244.77 10
Total: 10
More

Institutions Volume Share, %
NEA Management Company, LLC 4426151 9.67
8vc Gp I, LLC 2537558 5.55
ARK Investment Management, LLC 1969860 4.31
Vanguard Group Inc 707052 1.55
Intel Corporation 595665 1.3
Triatomic Management Lp 310533 0.68
Geode Capital Management, LLC 238406 0.52
Omega Fund Management, Llc 195792 0.43
Bridgeway Capital Management, Inc. 145000 0.32
Artal Group S.A. 55555 0.12



Head Job title Payment Year of birth
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, CEO & Director 868.57k 1981 (44 years)
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 58.5k 1966 (59 years)
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer 689.99k 1974 (51 year)
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board N/A
Ms. Yvonne Li M.B.A. Interim CFO, Treasurer & Principal Accounting Officer 1960 (65 years)
Mr. Thomas P. Chung Vice President of Strategic Finance & Corporate Development
Ms. Dee Olomajeye Dragon Vice President of People Strategy & Culture

Address: United States, South San Francisco. CA, 2 Corporate Drive - open in Google maps, open in Yandex maps
Website: https://www.sentibio.com